ClinicalTranscatheter valve-in-valve replacement of degenerated bioprosthetic aortic valves: A single Australian Centre experience
Introduction
Bioprosthetic aortic valves have been preferred to mechanical valves for the elderly and those at high risk of bleeding on anticoagulant therapy, but with improvement in design and growing experience there has been a trend to implanting them in younger patients [1], [2], [3]. Unfortunately they may be subject to structural degeneration and failure after 10–20 years [4], [5]. Surgical valve replacement is the standard of care for patients with failed valves but may be hazardous, particularly for elderly patients with multiple comorbidities [4], [6], [7], [8], [9], [10], [11]. Transcatheter aortic valve implantation (TAVI) has come to be seen as an alternative, but experience is still limited to several hundred patients worldwide [12], [13], [14], [15], [16], [17], [18], [19], [20], [21]. We report our experience with this procedure over the past five years.
Between May 2009 and February 2014 1625 patients have undergone surgical aortic valve replacement in our institution (Fig. 1), 1162 (71.5%) with bioprosthetic valves and 463 with mechanical valves. These included 126 (7.8%) who had second or subsequent operations for failed bioprostheses. Two hundred and sixty two (13.9% of all aortic valve replacement patients) who were at extremely high risk for surgery underwent TAVI [22], including 12 who had a valve-in-valve (ViV) procedure (Fig. 1, Table 1).
These patients were symptomatic with dyspnœa (NYHA class 3.1 ± 0.6). Six of them had had 2 or more previous thoracotomies, and 6 had significant coronary artery disease including 4 who had undergone coronary bypass grafting. Their mean age was 78 ± 7 years, body mass index 27 ± 5 kg/m2, left ventricular ejection fraction 58 ± 11% and Society of Thoracic Surgeons mortality score 6.7 ± 3.7. The interval since their most recent valve surgery was 10 ± 4 (range 3–16) years. Six of the prosthetic aortic valves were severely stenotic (valve area ≤ 0.8 cm2), and 6 had significant (grade 3–4) regurgitation (Table 1).
All the patients had undergone assessment of their symptomatic status, comorbidities and the mode of prosthetic valve failure. Imaging included transthoracic (TTE) and transœsophageal echocardiography (TOE), multi-detector computed tomography (MDCT), selective catheterisation and angiography to define prosthetic valve morphology, hæmodynamics, vascular access and coronary artery disease.
We obtained the design characteristics of the surgically implanted bioprosthetic valves from the operation reports and information supplied by the companies. The valve dimensions were confirmed with echocardiographic and MDCT measurements.
Our multi-disciplinary team which includes cardiologists, cardiothoracic surgeons with extensive experience in valve replacement and anæsthetists evaluated them for further surgery: all were considered to be at unduly high risk. They gave informed consent for the procedure and data collection.
The procedures were undertaken in a hybrid catheterization laboratory. Valve deployment was achieved through femoral, subclavian, transaortic or transapical routes. The techniques of vascular access and approach to the aortic valve were similar to those for TAVI in native valves [23]. TOE guidance was employed in all but #1, #2 and #5 and temporary pacing in all. Rapid (burst) pacing was used at the time of valve deployment in 6 patients (#3, #4, #6, #9, #10 and #12) and balloon dilatation of stenotic bioprostheses in 4 (#2, #3, #4 and #5) and to reduce paravalvar regurgitation of a CoreValve® (#12).
Valves were successfully implanted in all the patients (Table 1). The resultant mean valve gradients were 15 ± 8 mm Hg (median 12, range 5 → 32 mm Hg) and the indexed effective orifice areas 0.93 ± 0.22 cm2.m2 (median 0.87, range 0.65 → 1.30 cm2.m2). The volume of contrast used was 158 ± 182 ml and the dose-area product 17458 ± 16971 Gy*cm2.
Following pre-dilatation of the bioprosthetic valve patient #4 developed torrential aortic regurgitation and asystolic cardiac arrest which were managed with cardiopulmonary resuscitation and immediate prosthetic valve implantation.
We inserted a CoreValve® within a Toronto™ stentless bioprosthesis in patient #7. Immediately following its release it became displaced towards the coronary ostia. A gooseneck snare was used to reposition it in the ascending aorta, and a second CoreValve® was deployed with a good hæmodynamic result (Fig. 2).
Three patients developed left bundle branch block following CoreValve® implantation, 2 others required permanent pacemaker implantation and patient #3 with stage 3 chronic kidney disease needed temporary hæmodialysis. There were no neurological events, major vascular complications or deaths in hospital.
All patients were discharged from hospital in NYHA class I or II functional status. None had suffered a neurological event, major vascular complication or myocardial infarction, and had been readmitted or required further intervention (Table 1).
Four patients (#3, #4, #10, #12) had prosthesis–patient mismatch (PPM) [24], [25], [26], [27] with indexed effective orifice area ≤ 0.80 cm2.m2 and 2 (#3, #11) trans-valvular peak velocity ≥ 4 m.s− 1 and mean gradient ≥ 22 mm Hg. Three (#1, #5 and #10) had aortic regurgitation ≤ 2/4 and one (#9) valvular and para-valvular leaks ≥ grade 3/4.
Patient #6 had a routine surveillance trans-thoracic echocardiogram 9 months after TAVI which disclosed type A dissection of the aortic root. It is unclear whether this was related to aortic cannulation or to disease of her aorta, which had been noted to be dilated (50 mm) at the time of her initial assessment [28]. She survived following surgical replacement of her aortic root.
Two patients (#1, #2) died after 54 and 44 months: median survival for the 10 remaining has exceeded 19 months.
Section snippets
Discussion
TAVI has been shown to improve longevity and improve quality of life for those for whom surgical valve replacement carries excessive risk [29], [30]. With increasing experience this minimally invasive procedure has been extended to patients with failed surgical bioprosthetic valves who are inoperable or at high risk for further open surgery. The first successful ViV implantation in the aortic position was reported in 2007 [31]. Since then several reports [12], [15], [16], [17], [18], [19], [20]
Conclusion
Transcatheter ViV deployment is a safe and feasible treatment for high surgical risk patients with failed bioprosthetic aortic valves (1) using both Edwards® and CoreValve® prostheses, (2) for both stented or stentless bioprostheses, (3) for both stenosis and regurgitation, and (4) through various access routes—transfemoral, trans-subclavian, transapical and transaortic [28]. We have also confirmed the favourable hæmodynamic performance of percutaneously implanted valves and short to medium
Acknowledgments
We received no financial support for this study.
References (44)
- et al.
Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons national database
J Thorac Cardiovasc Surg
(2009) - et al.
Allograft aortic valve replacement: long-term follow-up
Ann Thorac Surg
(1995) - et al.
Results of reoperation for primary tissue failure of porcine bioprostheses
J Thorac Cardiovasc Surg
(1985) - et al.
Valve-in-valve transcatheter aortic valve implantation for degenerated bioprosthetic heart valves
JACC Cardiovasc Interv
(2011) - et al.
Reoperations for valve surgery: perioperative mortality and determinants of risk for 1,000 patients, 1958-1984
Ann Thorac Surg
(1986) - et al.
Hospital mortality of re-replacement of the aortic valve. Incremental risk factors
J Thorac Cardiovasc Surg
(1981) - et al.
Transapical aortic valve implantation after previous aortic valve replacement: clinical proof of the "valve-in-valve" concept
J Thorac Cardiovasc Surg
(2011) - et al.
Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 1)
JACC Cardiovasc Interv
(2011) - et al.
Transcatheter valve-in-valve implantation for deteriorated aortic bioprosthesis: initial clinical results and follow-up in a series of high-risk patients
Ann Thorac Surg
(2012) - et al.
New Corevalve Evolut 23 mm technology for treatment of degenerated bioprosthesis
Heart Lung Circ
(2014)
Initial experience with the balloon expandable Edwards-SAPIEN Transcatheter Heart Valve in Australia and New Zealand: the SOURCE ANZ registry: outcomes at 30 days and one year
Int J Cardiol
Hemodynamic and clinical impact of prosthesis-patient mismatch after transcatheter aortic valve implantation
J Am Coll Cardiol
Early experience of transaortic TAVI-the future of surgical TAVI?
Heart Lung Circ
Transcatheter aortic valve implantation for failing surgical aortic bioprosthetic valve: from concept to clinical application and evaluation (part 2)
JACC Cardiovasc Interv
Aortic annulus diameter determination by multidetector computed tomography: reproducibility, applicability, and implications for transcatheter aortic valve implantation
JACC Cardiovasc Interv
Inaccurate and misleading valve sizing: a proposed standard for valve size nomenclature
Ann Thorac Surg
Fluoroscopic guide to an ideal implant position for Sapien XT and CoreValve during a valve-in-valve procedure
JACC Cardiovasc Interv
Transapical off-pump valve-in-valve implantation in patients with degenerated aortic xenografts
Ann Thorac Surg
Problems encountered with catheter balloon valvuloplasty of bioprosthetic aortic valves
Am Heart J
Distortion of the Corevalve during transcatheter aortic valve-in-valve implantation due to valve dislocation
Cardiovasc Revasc Med
Repeat heart valve surgery: risk factors for operative mortality
J Thorac Cardiovasc Surg
Reoperation after fresh homograft replacement: 23 years' experience with 655 patients
Eur J Cardiothorac Surg
Cited by (11)
Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration
2017, Journal of the American College of CardiologyCitation Excerpt :In these patients, valve-in-valve procedures have been associated with a high rate (95%) of successful valve implantation and a mean 30-day mortality of 8% (7). The periprocedural outcomes of valve-in-valve procedures are summarized in Table 7 (74–87). Of note, some aspects of valve-in-valve procedures differ from conventional TAVR procedures (Table 8) (7,84).
Transapical Transcatheter Mitral Valve-in-Valve Implantation Using an Edwards SAPIEN 3 Valve
2017, Heart Lung and CirculationCitation Excerpt :Due to their invariable structural deterioration, the number of patients presenting for reoperations for degenerative bioprosthetic valves continues to rise. The establishment of transcatheter valve implantation in high-risk aortic stenosis patients has seen its application expand to treatment of similarly high-risk surgical patients with degenerated aortic [2] or mitral valve bioprostheses [3]. Since its first description in a human in 2009 [4], several studies have demonstrated the feasibility of transcatheter mitral valve-in-valve (MVIV) implantation using Edwards SAPIEN (Edwards Lifesciences, Irvine, CA) and SAPIEN XT valves.
Clinical outcomes for transcatheter valve-in-valve in treating surgical bioprosthetic dysfunction: A meta-analysis
2016, International Journal of CardiologyLong Term Outcomes Following Freestyle Stentless Aortic Bioprosthesis Implantation: An Australian Experience
2016, Heart Lung and CirculationCitation Excerpt :The mortality risk associated with redo aortic root surgery is elevated compared with first-time surgery, but has been shown to be acceptable and may be reduced to <5% in experienced hands [17–19]. As an alternative approach, several reports have demonstrated acceptable clinical outcomes following ‘valve-in-valve’ transcatheter treatment of prosthetic SVD (including following porcine stentless valve surgery) [20,21]. Currently, the transcatheter approach remains reserved for high-risk patients and its suitability in the long term for treatment of prosthetic SVD remains to be seen.
Transcatheter valve-in-valve and valve-in-ring for treating aortic and mitral surgical prosthetic dysfunction
2015, Journal of the American College of CardiologyCitation Excerpt :Table 3 condenses the relative frequencies of the main complications associated with each type of procedure. Only a few valve-in-valve studies have reported 1-year survival rates (10,56,57,59–65). The mean mortality rate at 1 year has been 15.1% (ranging from 0% to 16.8%) (Table 2).